EMA Grants PRIME Eligibility for KB103 to Treat DEB

Krystal Biotech announced that the European Medicines Agency (EMA) has given KB103, Krystal's topical gene therapy candidate for treatment of DEB, PRIME (PRIority MEdicines) designation, which is awarded to promising treatments that target an unmet medical need. Through the PRIME program, the EMA offers support to expedite the path to drug evaluation. ​

READ MORE